Flumequine

Identification

Name
Flumequine
Accession Number
DB08972
Type
Small Molecule
Groups
Withdrawn
Description

Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
UVG8VSP2SJ
CAS number
42835-25-6
Weight
Average: 261.2484
Monoisotopic: 261.08012146
Chemical Formula
C14H12FNO3
InChI Key
DPSPPJIUMHPXMA-UHFFFAOYSA-N
InChI
InChI=1S/C14H12FNO3/c1-7-2-3-8-4-9(15)5-10-12(8)16(7)6-11(13(10)17)14(18)19/h4-7H,2-3H2,1H3,(H,18,19)
IUPAC Name
7-fluoro-12-methyl-4-oxo-1-azatricyclo[7.3.1.0⁵,¹³]trideca-2,5(13),6,8-tetraene-3-carboxylic acid
SMILES
CC1CCC2=CC(F)=CC3=C2N1C=C(C(O)=O)C3=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Flumequine.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Flumequine.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Flumequine.Experimental, Illicit
AcarboseFlumequine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
AcemetacinAcemetacin may increase the neuroexcitatory activities of Flumequine.Approved, Experimental, Investigational
AcenocoumarolFlumequine may increase the anticoagulant activities of Acenocoumarol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Flumequine.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Flumequine.Experimental
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Flumequine.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Flumequine.Approved
AlbiglutideFlumequine may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacAlclofenac may increase the neuroexcitatory activities of Flumequine.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Flumequine.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Flumequine.Experimental, Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenAlminoprofen may increase the neuroexcitatory activities of Flumequine.Experimental
AlogliptinFlumequine may increase the hypoglycemic activities of Alogliptin.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AluminiumAluminium can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Flumequine.Experimental, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Flumequine.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Flumequine.Approved
AndrographolideAndrographolide may increase the neuroexcitatory activities of Flumequine.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Flumequine.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Flumequine.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Flumequine.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Flumequine.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Flumequine.Approved
ApocyninApocynin may increase the neuroexcitatory activities of Flumequine.Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Flumequine.Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Flumequine.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Flumequine.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Flumequine.Approved, Investigational
BendazacBendazac may increase the neuroexcitatory activities of Flumequine.Experimental
BenorilateBenorilate may increase the neuroexcitatory activities of Flumequine.Experimental
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Flumequine.Withdrawn
BenzydamineBenzydamine may increase the neuroexcitatory activities of Flumequine.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Flumequine.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Flumequine.Approved, Investigational
BevoniumBevonium may increase the neuroexcitatory activities of Flumequine.Experimental
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BromfenacBromfenac may increase the neuroexcitatory activities of Flumequine.Approved
BromocriptineFlumequine may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the neuroexcitatory activities of Flumequine.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Flumequine.Approved
BufexamacBufexamac may increase the neuroexcitatory activities of Flumequine.Experimental
BumadizoneBumadizone may increase the neuroexcitatory activities of Flumequine.Experimental
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Flumequine.Approved
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CitrateCalcium Citrate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Calcium lactateCalcium lactate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium laevulateCalcium laevulate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium pangamateCalcium pangamate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium PhosphateCalcium Phosphate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinFlumequine may increase the hypoglycemic activities of Canagliflozin.Approved
CarprofenCarprofen may increase the neuroexcitatory activities of Flumequine.Approved, Vet Approved, Withdrawn
CaseinCasein can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CastanospermineCastanospermine may increase the neuroexcitatory activities of Flumequine.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
ChloroquineChloroquine may increase the neuroexcitatory activities of Flumequine.Approved, Vet Approved
ChlorpropamideFlumequine may increase the hypoglycemic activities of Chlorpropamide.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the neuroexcitatory activities of Flumequine.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Flumequine.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Flumequine.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Flumequine.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Flumequine.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Flumequine.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Flumequine.Approved
ClorindioneFlumequine may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Flumequine.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Flumequine.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Flumequine.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Flumequine.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Flumequine.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Flumequine.Experimental
D-LimoneneD-Limonene may increase the neuroexcitatory activities of Flumequine.Investigational
DapagliflozinFlumequine may increase the hypoglycemic activities of Dapagliflozin.Approved
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Flumequine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Flumequine.Approved
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Flumequine.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Flumequine.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Flumequine.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Flumequine.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Flumequine.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Flumequine.Vet Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Flumequine.Approved, Vet Approved
DicoumarolFlumequine may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Flumequine.Approved
DifenpiramideDifenpiramide may increase the neuroexcitatory activities of Flumequine.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Flumequine.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Flumequine.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Flumequine.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Flumequine.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Flumequine.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Flumequine.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Flumequine.Approved
DiphenadioneFlumequine may increase the anticoagulant activities of Diphenadione.Experimental
DisopyramideFlumequine may increase the hypoglycemic activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Flumequine.Approved, Investigational
DroxicamDroxicam may increase the neuroexcitatory activities of Flumequine.Approved
DulaglutideFlumequine may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibDuvelisib may increase the neuroexcitatory activities of Flumequine.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Flumequine.Approved
E-6201E-6201 may increase the neuroexcitatory activities of Flumequine.Investigational
EmpagliflozinFlumequine may increase the hypoglycemic activities of Empagliflozin.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Flumequine.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Flumequine.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Flumequine.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Flumequine.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Flumequine.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
EthenzamideEthenzamide may increase the neuroexcitatory activities of Flumequine.Experimental
Ethyl biscoumacetateFlumequine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Flumequine.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
ExenatideFlumequine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindexisulind may increase the neuroexcitatory activities of Flumequine.Investigational
FelbinacFelbinac may increase the neuroexcitatory activities of Flumequine.Experimental
FenbufenFenbufen may increase the neuroexcitatory activities of Flumequine.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Flumequine.Approved
FentiazacFentiazac may increase the neuroexcitatory activities of Flumequine.Experimental
FeprazoneFeprazone may increase the neuroexcitatory activities of Flumequine.Experimental
Ferric CarboxymaltoseThe serum concentration of Flumequine can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Flumequine can be decreased when it is combined with Ferric Citrate.Approved, Investigational
Ferric pyrophosphateThe serum concentration of Flumequine can be decreased when it is combined with Ferric pyrophosphate.Approved
Ferulic acidFerulic acid may increase the neuroexcitatory activities of Flumequine.Experimental
FloctafenineFloctafenine may increase the neuroexcitatory activities of Flumequine.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Flumequine.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Flumequine.Approved
FluindioneFlumequine may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Flumequine.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Flumequine.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Flumequine.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the neuroexcitatory activities of Flumequine.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Flumequine.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Flumequine.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Flumequine.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Flumequine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Flumequine.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Flumequine.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Flumequine.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Flumequine.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Flumequine.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Flumequine.Approved, Investigational, Withdrawn
GitoformateGitoformate may decrease the cardiotoxic activities of Flumequine.Experimental
GliclazideFlumequine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideFlumequine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideFlumequine may increase the hypoglycemic activities of Glipizide.Approved
GlyburideFlumequine may increase the hypoglycemic activities of Glyburide.Approved
GuacetisalGuacetisal may increase the neuroexcitatory activities of Flumequine.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Flumequine.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Flumequine.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Flumequine.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Flumequine.Approved, Vet Approved
HydrotalciteHydrotalcite can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
IbuprofenIbuprofen may increase the neuroexcitatory activities of Flumequine.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Flumequine.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Flumequine.Approved
Imidazole salicylateImidazole salicylate may increase the neuroexcitatory activities of Flumequine.Experimental
IndobufenIndobufen may increase the neuroexcitatory activities of Flumequine.Investigational
IndomethacinIndomethacin may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Flumequine.Withdrawn
Insulin AspartFlumequine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirFlumequine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineFlumequine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineFlumequine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanFlumequine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproFlumequine may increase the hypoglycemic activities of Insulin Lispro.Approved
IronThe serum concentration of Flumequine can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Flumequine can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Flumequine can be decreased when it is combined with Iron saccharate.Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Flumequine.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Flumequine.Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Flumequine.Experimental
KetoprofenKetoprofen may increase the neuroexcitatory activities of Flumequine.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Flumequine.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Flumequine.Experimental
Lanthanum carbonateThe serum concentration of Flumequine can be decreased when it is combined with Lanthanum carbonate.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
LiraglutideFlumequine may increase the hypoglycemic activities of Liraglutide.Approved
LisofyllineLisofylline may increase the neuroexcitatory activities of Flumequine.Investigational
LonazolacLonazolac may increase the neuroexcitatory activities of Flumequine.Experimental
LornoxicamLornoxicam may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Flumequine.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateThe serum concentration of Flumequine can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium SulfateThe serum concentration of Flumequine can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Flumequine.Investigational
MecaserminFlumequine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Flumequine.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Flumequine.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Flumequine.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Flumequine.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Flumequine.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Flumequine.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Flumequine.Investigational, Withdrawn
MetforminFlumequine may increase the hypoglycemic activities of Metformin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Flumequine.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Flumequine.Experimental
MifepristoneFlumequine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolFlumequine may increase the hypoglycemic activities of Miglitol.Approved
MizoribineMizoribine may increase the neuroexcitatory activities of Flumequine.Investigational
MofebutazoneMofebutazone may increase the neuroexcitatory activities of Flumequine.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Flumequine.Approved, Vet Approved
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Flumequine.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Flumequine.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Flumequine.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Flumequine.Approved, Vet Approved
NateglinideFlumequine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Flumequine.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Flumequine.Approved
NifenazoneNifenazone may increase the neuroexcitatory activities of Flumequine.Experimental
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Flumequine.Approved
NimesulideNimesulide may increase the neuroexcitatory activities of Flumequine.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Flumequine.Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Flumequine.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Flumequine.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Flumequine.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Flumequine.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Flumequine.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Flumequine.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Flumequine.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Flumequine.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Flumequine.Approved, Vet Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Flumequine.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Flumequine.Approved
ParthenolideParthenolide may increase the neuroexcitatory activities of Flumequine.Investigational
PentamidineFlumequine may increase the hypoglycemic activities of Pentamidine.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Flumequine.Experimental
PhenindioneFlumequine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonFlumequine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Flumequine.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
PioglitazoneFlumequine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
PirprofenPirprofen may increase the neuroexcitatory activities of Flumequine.Experimental
PramlintideFlumequine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenPranoprofen may increase the neuroexcitatory activities of Flumequine.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Flumequine.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Flumequine.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Flumequine.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Flumequine.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Flumequine.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Flumequine.Experimental, Investigational
ProbenecidThe serum concentration of Flumequine can be increased when it is combined with Probenecid.Approved
ProglumetacinProglumetacin may increase the neuroexcitatory activities of Flumequine.Experimental
PropacetamolPropacetamol may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
PropyphenazonePropyphenazone may increase the neuroexcitatory activities of Flumequine.Experimental
ProquazoneProquazone may increase the neuroexcitatory activities of Flumequine.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Flumequine.Experimental
PTC299PTC299 may increase the neuroexcitatory activities of Flumequine.Investigational
QuinaprilThe serum concentration of Flumequine can be decreased when it is combined with Quinapril.Approved, Investigational
QuinineFlumequine may increase the hypoglycemic activities of Quinine.Approved
RepaglinideFlumequine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Flumequine.Approved, Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Flumequine.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Flumequine.Investigational, Withdrawn
RosiglitazoneFlumequine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SalicylamideSalicylamide may increase the neuroexcitatory activities of Flumequine.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Flumequine.Approved, Vet Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Flumequine.Approved
SaxagliptinFlumequine may increase the hypoglycemic activities of Saxagliptin.Approved
SemapimodSemapimod may increase the neuroexcitatory activities of Flumequine.Investigational
SeratrodastSeratrodast may increase the neuroexcitatory activities of Flumequine.Approved
SerrapeptaseSerrapeptase may increase the neuroexcitatory activities of Flumequine.Investigational
SevelamerSevelamer can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SitagliptinFlumequine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Flumequine.Investigational
Strontium ranelateThe serum concentration of Flumequine can be decreased when it is combined with Strontium ranelate.Approved
SucralfateThe serum concentration of Flumequine can be decreased when it is combined with Sucralfate.Approved
SulfadiazineFlumequine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleFlumequine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Flumequine.Approved
SulfisoxazoleFlumequine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Flumequine.Approved
SunitinibFlumequine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Flumequine.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the neuroexcitatory activities of Flumequine.Experimental
TarenflurbilTarenflurbil may increase the neuroexcitatory activities of Flumequine.Investigational
TenidapTenidap may increase the neuroexcitatory activities of Flumequine.Experimental
TenoxicamTenoxicam may increase the neuroexcitatory activities of Flumequine.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Flumequine.Vet Approved
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Flumequine.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Flumequine.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Flumequine.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Flumequine.Investigational
TioclomarolFlumequine may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Flumequine.Approved
TolazamideFlumequine may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideFlumequine may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Flumequine.Approved
TolmetinTolmetin may increase the neuroexcitatory activities of Flumequine.Approved
TranilastTranilast may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Flumequine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Flumequine.Approved, Vet Approved
TribenosideTribenoside may increase the neuroexcitatory activities of Flumequine.Experimental
TriptolideTriptolide may increase the neuroexcitatory activities of Flumequine.Investigational
TromethamineTromethamine can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Flumequine.Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Flumequine.Investigational, Withdrawn
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Flumequine.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Flumequine.Approved
WarfarinFlumequine may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Flumequine.Approved, Investigational
ZileutonZileuton may increase the neuroexcitatory activities of Flumequine.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the neuroexcitatory activities of Flumequine.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 3,896,131.

General References
Not Available
External Links
Human Metabolome Database
HMDB41895
PubChem Compound
3374
PubChem Substance
310264935
ChemSpider
3257
ChEBI
94431
ChEMBL
CHEMBL370252
ATC Codes
J01MB07 — Flumequine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.24 mg/mLALOGPS
logP1.62ALOGPS
logP2.42ChemAxon
logS-2.3ALOGPS
pKa (Strongest Acidic)6ChemAxon
pKa (Strongest Basic)-4.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area57.61 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity67.87 m3·mol-1ChemAxon
Polarizability25.25 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0090000000-4562bd1b09907dc3b700
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0uk9-0190000000-0bac3ec6458648a725c0
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0fk9-0980000000-91b57386bd019dd7838b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0090000000-938a6d39c487a729e57e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03dl-0090000000-73779217b6427d238ce0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01ox-0090000000-13657a0f167139ce56f3
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0h2f-0090000000-def6112d5472cfde4da7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0fk9-0190000000-56e0b22aa033cf49c8c0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0fk9-0980000000-e04498a4742bec91275e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ufs-2900000000-068e7a9b1ae656d70d01
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0f92-9800000000-b99a0e425235a9128533
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0f6t-9300000000-164deed4d2600172d871
MS/MS Spectrum - , positiveLC-MS/MSsplash10-01ox-0090000000-7b3c06efa7853de57efb
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0ukc-2690000000-7afb48e267c7b334213b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0090000000-9604f2662310bea2bfe7

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Fluoroquinolones / Haloquinolines / Hydroquinolones / Hydroquinolines / Pyridinecarboxylic acids / Aryl fluorides / Benzenoids / Heteroaromatic compounds / Vinylogous amides / Monocarboxylic acids and derivatives
show 8 more
Substituents
Quinoline-3-carboxylic acid / Fluoroquinolone / Dihydroquinolone / Haloquinoline / Dihydroquinoline / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Benzenoid / Pyridine / Aryl fluoride
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organofluorine compound, quinolone antibiotic, 3-oxo monocarboxylic acid, pyridoquinoline (CHEBI:85269)

Drug created on June 09, 2014 10:39 / Updated on November 09, 2017 04:43